# HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Source: https://onco.cc/trials/nct06149247/  
OnCo record `nct06149247` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Synthetic hypericin in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by Soligenix, completed.

## Summary

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL is a phase 2 interventional study registered as NCT06149247 by Soligenix, with 10 participants recorded, started 2023-12-05 and reaching its primary completion in 2024-05-31. Interventions recorded: Hypericin, Mechlorethamine Topical Gel. Conditions recorded: Cutaneous T-Cell Lymphoma/Mycosis Fungoides.

Linked to the drug Synthetic hypericin because the registry names it among its interventions and Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06149247
- Phase: 2
- Setting: Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
- Sponsor: Soligenix
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT06149247: https://clinicaltrials.gov/study/NCT06149247

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- drugs: [Synthetic hypericin](https://onco.cc/drugs/hypericin-sgx301/)
- companies: [Soligenix](https://onco.cc/companies/soligenix/)

---
JSON: https://onco.cc/api/v1/entities/nct06149247.json